RE:Another update I wish her and your family strength, peace and Godspeed for one last journey. Heartfelt sympathy and that your faith gets you through it together and raises her spirits so she enjoys her time with family. Very sorry to hear.
Your clues are helpful and as we know it's all very complicated for late stage refractory and based on larger samples to be conclusive around anything. I look at it quite positively from a POC standpoint.
The peptide hits its target with very little free taxol in the blood. Side effects seem much less than IV admin but hard to tell except for the no hair loss clue, but that is positive.
For the tumors it clearly gets internalized, that part seems to work assuming they were the overexpressed tumors. More than anything it sounds like there weren't enough cycles for the drug to really accumulate and do it's thing widely (hence the mixture of regress and growth) and perhaps the metastices phase was far too along in this case. I recall their work on metastices had multiple treatments and the best results were when they combined it with another agent. Like QWERTY says, total tumor burden may have some effect on what would be the best dosage size and maybe advanced metastatic requires something higher or more powerful. The fact the cancer markers saw a substantial drop is a great initial indication there is a positive effect happening. Unfortunately just sounds like you are saying time wasn't favorable in this specific situation and maybe for her type of cancer.
So net-net, I lean toward seeing more positive indications as it "appears" to be very safe and tolerated, lowers important markers, sort1 gets it in to tumors (but not all so maybe more toxin via more cycles was needed). Any chemo needs many cycles to saturate it and logically targeted therapies relying on genetic markers need more as you look to find the sort1 wherever it eventually gets overexpressed. The complications around very late stage are a challenge that probably needs many cycles to overcome. I like the rapid recruitment comment too.
juniper88 wrote: My wife has been move to to Princess Margaret palliative care so that she may be comfortable in whatever time she has left. I have know many of you for many years and I am appreciative of all the good thoughts and prayers. It is a very difficult time for our family, but still I feel the pull to let you all know what I have seen from the phase 1 trial my wife was on. I am writing this post from my cell phone, so everything appears in one paragraph. First, I will disclose that I sold about 10k TH shares because i need the money to pay for the funeral, burial, etc. The second disclosure is that my wife was one the TH1902 trial. We got CT scan reports back earlier this week that showed both regression and progression of tumors. I know for sure that TH1901 works. We can see that from the tumors that regressed and the substantial lowering in my wife's tumor marker. These trials are about research, getting more information. Efficacy would be great but it is complicated. On July 1st I noticed that my wife's eye became yellow again. A few days later she had deteriorated and I toke her to the ER, where they rushed her inside. They did the CT scans and found abscesses in the liver and that the bile duct stent had become blocked. They told me that she had a severe bacterial infection likely originating from the stent, but it also could just be the cancer. We were offered a procedure to replace the stent but we declined, as it would ultimately not change the outcome. The question about the trial I have is why did only some tumors regress? Was it because those tumors did not have SORT1? Or was docetaxel not effective against those? My wife got the 300mg/m2 dosage. She lost almost now hair which tells us that there was very little free docetaxel in her blood. That would also tell us that the tumor regression came because TH1902 rather than free docetaxel. Ovarian cancer is very heterogeneous. So it is very possible that the tumors that progressed were a cancer line resistant in some other way. A more powerful bomb would help. On the other hand if those tumors didn't over express SORT1 then the TH1901 simply wouldn't work against those tumors. Also about the trial, the weekly blood work is onerous on late stage cancer patients. It might even keep some patients out of the trial. But from what I know, recruitment is happening fast.